Analysts Set Expectations for CGTX FY2026 Earnings

Key Points

• Brookline Capital Markets raised its FY2026 EPS estimate for Cognition Therapeutics to a loss of $0.20 per share from a projected $0.42 loss; its Q4 2026 estimate is a $0.06-per-share loss. The full-year consensus estimate is a $0.30 loss per share.
• CGTX reported a quarterly loss of $0.04 per share, beating analysts’ expected $0.07 loss by $0.03. The stock opened at $0.69, within its 12-month range of $0.55 to $1.82.
• Analyst ratings are mixed but average to a “Moderate Buy,” with three Buy ratings and one Sell rating and an average price target of $3.33.

Cognition Therapeutics, Inc. (NASDAQ:CGTX - Free Report) - Equities researchers at Brookline Capital Markets lifted their FY2026 EPS estimates for Cognition Therapeutics in a research report issued to clients and investors on Thursday, November 5th. Brookline Capital Markets analyst F. Ahmed now expects that the company will earn ($0.20) per share for the year, up from their previous estimate of ($0.42). The consensus estimate for Cognition Therapeutics' current full-year earnings is ($0.30) per share. Brookline Capital Markets also issued estimates for Cognition Therapeutics' Q4 2026 earnings at ($0.06) EPS.

Other research analysts have also issued reports about the company. Wall Street Zen lowered Cognition Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, August 15th. Weiss Ratings restated a "sell (d-)" rating on shares of Cognition Therapeutics in a research note on Monday, September 21st. Finally, HC Wainwright restated a "buy" rating on shares of Cognition Therapeutics in a research note on Monday, October 5th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Cognition Therapeutics has an average rating of "Moderate Buy" and an average price target of $3.33.

Cognition Therapeutics Price Performance

NASDAQ CGTX opened at $0.69 on Tuesday. Cognition Therapeutics has a 12 month low of $0.55 and a 12 month high of $1.82. The stock has a 50 day moving average of $0.87 and a 200-day moving average of $1.05.

Cognition Therapeutics (NASDAQ:CGTX - Get Free Report) last released its earnings results on Thursday, November 5th. The company reported ($0.04) earnings per share for the quarter, beating analysts' consensus estimates of ($0.07) by $0.03.

Institutional Trading of Cognition Therapeutics

Several hedge funds have recently added to or reduced their stakes in CGTX. BlackRock Inc. acquired a new position in Cognition Therapeutics in the 2nd quarter valued at $1,451,000. Renaissance Technologies LLC increased its position in Cognition Therapeutics by 15.2% during the 1st quarter. Renaissance Technologies LLC now owns 1,117,136 shares of the company's stock worth $848,000 after buying an additional 147,623 shares during the period. Sigma Planning Corp lifted its holdings in shares of Cognition Therapeutics by 7.3% during the second quarter. Sigma Planning Corp now owns 362,265 shares of the company's stock worth $417,000 after buying an additional 24,500 shares in the last quarter. Tocqueville Asset Management L.P. acquired a new stake in shares of Cognition Therapeutics during the second quarter worth $369,000. Finally, Texas Capital Bank Wealth Management Services Inc bought a new stake in shares of Cognition Therapeutics in the second quarter valued at about $165,000. 43.35% of the stock is owned by institutional investors and hedge funds.

About Cognition Therapeutics

Cognition Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company's research centers on the sigma-2 receptor, also known as the sigma-2 receptor complex or PGRMC1, a target believed to play a role in the cellular mechanisms associated with synaptic dysfunction and neurodegeneration.

Cognition Therapeutics' lead product candidate is CT1812, an orally administered small-molecule therapy designed to modulate the sigma-2 receptor complex.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.